Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$4 Mln
P/E Ratio
--
P/B Ratio
2.43
Industry P/E
--
Debt to Equity
0.02
ROE
-3.22 %
ROCE
-317.34 %
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-24.36 Mln
EBITDA
$-28.46 Mln
Net Profit
$-32.08 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Painreform (PRFX)
| -29.96 | -10.31 | -34.17 | -88.57 | -80.14 | -- | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
|
|---|---|---|---|
|
Painreform (PRFX)
| -33.37 | -68.95 | -70.25 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 6.69 | 384.71 | 26.76 | 5.74 | |
| 18.08 | 195.40 | -- | -96.33 | |
| 2.60 | 27.16 | -- | -1038.73 | |
| 0.29 | 3.16 | -- | -72.84 |
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based... solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel. Read more
Executive Chairman
Dr. Ehud Geller Ph.D.
Executive Chairman
Dr. Ehud Geller Ph.D.
Headquarters
Tel Aviv
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Painreform Ltd (PRFX) stood at $ 5 Mln as on 31-Dec-24
The share price of Painreform Ltd (PRFX) is $2.35 (NASDAQ) as of 25-Apr-2025 16:01 EDT. Painreform Ltd (PRFX) has given a return of -80.14% in the last 3 years.
Painreform Ltd (PRFX) has a market capitalisation of $ 4 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Painreform Ltd (PRFX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Painreform Ltd (PRFX) and enter the required number of quantities and click on buy to purchase the shares of Painreform Ltd (PRFX).
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
The CEO & director of Dr. Ehud Geller Ph.D.. is Painreform Ltd (PRFX), and CFO & Sr. VP is Dr. Ehud Geller Ph.D..
There is no promoter pledging in Painreform Ltd (PRFX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
35
|
|
|
19
|
|
|
2
|
|
|
0
|
| Painreform Ltd (PRFX) | Ratios |
|---|---|
|
Return on equity(%)
|
-321.92
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Painreform Ltd (PRFX) was $0 Mln.
$0.03
(
